Jinming Yu

493 total citations
25 papers, 328 citations indexed

About

Jinming Yu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Jinming Yu has authored 25 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Jinming Yu's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (7 papers) and Brain Metastases and Treatment (6 papers). Jinming Yu is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (7 papers) and Brain Metastases and Treatment (6 papers). Jinming Yu collaborates with scholars based in China, United States and Serbia. Jinming Yu's co-authors include Peng Xie, Xindong Sun, Minghuan Li, Zheng Fu, Hanxi Zhao, Chungang Wang, Jie Ma, Ke Ye, Hong Ge and Yanan Sun and has published in prestigious journals such as Journal of Clinical Oncology, Frontiers in Immunology and Cancer Letters.

In The Last Decade

Jinming Yu

22 papers receiving 325 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jinming Yu China 11 186 136 80 66 55 25 328
Songran Liu China 9 91 0.5× 147 1.1× 106 1.3× 62 0.9× 65 1.2× 28 328
Shengfu Huang China 11 98 0.5× 86 0.6× 79 1.0× 58 0.9× 152 2.8× 27 344
K. Kian Ang United States 7 107 0.6× 159 1.2× 171 2.1× 53 0.8× 89 1.6× 7 406
Kevin Lee Min Chua Singapore 10 211 1.1× 141 1.0× 52 0.7× 66 1.0× 13 0.2× 30 341
Ruping Zhao China 10 88 0.5× 89 0.7× 121 1.5× 26 0.4× 11 0.2× 26 261
Cornelius Maihoefer Germany 9 62 0.3× 53 0.4× 128 1.6× 37 0.6× 49 0.9× 9 297
Xianglin Yuan China 11 187 1.0× 210 1.5× 106 1.3× 55 0.8× 7 0.1× 28 439
Xiaoqing Xu China 12 67 0.4× 126 0.9× 105 1.3× 46 0.7× 7 0.1× 28 298
Qitao Yu China 12 219 1.2× 284 2.1× 188 2.4× 27 0.4× 10 0.2× 35 489
R. Ben Yosef Israel 6 147 0.8× 139 1.0× 114 1.4× 50 0.8× 5 0.1× 11 369

Countries citing papers authored by Jinming Yu

Since Specialization
Citations

This map shows the geographic impact of Jinming Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jinming Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jinming Yu more than expected).

Fields of papers citing papers by Jinming Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jinming Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jinming Yu. The network helps show where Jinming Yu may publish in the future.

Co-authorship network of co-authors of Jinming Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Jinming Yu. A scholar is included among the top collaborators of Jinming Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jinming Yu. Jinming Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mehta, Minesh P., Vinai Gondi, Manmeet S. Ahluwalia, et al.. (2024). Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases.. Journal of Clinical Oncology. 42(16_suppl). 2008–2008. 6 indexed citations
3.
Yuan, Meng, Zhong Tao, Fei Wu, et al.. (2024). LILRB2 inhibition enhances radiation sensitivity in non-small cell lung cancer by attenuating radiation-induced senescence. Cancer Letters. 593. 216930–216930. 10 indexed citations
4.
Li, Yingge, Jie Chen, Bin Wang, et al.. (2023). FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis. Drug Resistance Updates. 67. 100926–100926. 15 indexed citations
5.
6.
Meng, Xiangjiao, Yu Chen, Ligang Xing, et al.. (2022). PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials. BMJ Open Respiratory Research. 9(1). e001294–e001294. 1 indexed citations
7.
Wang, Yimeng, Yao Wang, Jinming Yu, & Xiangjiao Meng. (2022). The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues. Cancer Letters. 551. 215947–215947. 4 indexed citations
8.
9.
10.
Yu, Jinming, et al.. (2020). A case-control study of association between e-cigarettes with smoking tendency in adolescents. Chinese Journal of School Health. 1 indexed citations
11.
Wang, Zhe, Minghuan Li, Feifei Teng, Li Ren Kong, & Jinming Yu. (2019). <p>Primary tumor location is an important predictor of survival in pulmonary adenocarcinoma</p>. Cancer Management and Research. Volume 11. 2269–2280. 11 indexed citations
12.
Tang, Wenjie, Xiaolin Li, Xindong Sun, et al.. (2019). EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations. Lung Cancer. 136. 6–14. 26 indexed citations
13.
Xu, Yan, et al.. (2018). FOXA1 and CK7 expression in esophageal squamous cell carcinoma and its prognostic significance. Neoplasma. 65(3). 469–476. 11 indexed citations
14.
Li, Butuo, Cheng Li, Peng Xie, et al.. (2018). Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC. OncoTargets and Therapy. Volume 11. 6287–6294. 20 indexed citations
15.
Wang, Nannan, Xiangjiao Meng, Jia Wang, et al.. (2018). Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer. Oncology Reports. 41(1). 77–86. 28 indexed citations
16.
Zhu, Hui, Xiaoyan Ma, & Jinming Yu. (2017). PUB062 Risk Factors of Brain Metastasis during the Course of EGFR-TKIs Therapy for Patients with EGFR-Mutated Advanced Lung Adenocarcinoma. Journal of Thoracic Oncology. 12(1). S1484–S1484. 1 indexed citations
17.
Han, Guang, Min Peng, Yiming Weng, et al.. (2017). Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis. Current Medical Science. 37(6). 864–872. 4 indexed citations
18.
19.
Xie, Peng, et al.. (2016). Sequential Serum Let-7 Is a Novel Biomarker to Predict Accelerated Reproliferation During Fractional Radiotherapy in Lung Cancer. Clinical Lung Cancer. 17(5). e95–e101. 16 indexed citations
20.
Xie, Peng, Minghuan Li, Hanxi Zhao, et al.. (2011). 18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis. Journal of Cancer Research and Clinical Oncology. 137(7). 1085–1093. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Songran Liu Breakdown of academic impact, for papers by Shengfu Huang Breakdown of academic impact, for papers by K. Kian Ang Breakdown of academic impact, for papers by Kevin Lee Min Chua Breakdown of academic impact, for papers by Ruping Zhao Breakdown of academic impact, for papers by Cornelius Maihoefer Breakdown of academic impact, for papers by Xianglin Yuan Breakdown of academic impact, for papers by Xiaoqing Xu Breakdown of academic impact, for papers by Qitao Yu Breakdown of academic impact, for papers by R. Ben Yosef
Rankless by CCL
2026